Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 ...Middle East

Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ tumors With approximately two years of median follow-up, as of July 28, 2023, median...

Hence then, the article about jazz pharmaceuticals presents overall survival and longer follow up data from herizon btc 01 trial evaluating zanidatamab in previously treated her2 positive biliary tract cancer at asco 2024 was published today ( Saturday 01/06/2024 - 03:21 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 )

Also on site :

• Disgraced former Centinela Valley schools Superintendent Jose Fernandez dies
• Outsiders see a circular economy. CoreWeave’s CEO sees a ‘violent change’ rattling the supply chain down to the inside of the earth
• Tyler Perry Sued for Sexual Assault By New Accuser, an Actor in a ‘Madea’ Movie